Beta Drugs vs Kopran vs Sudarshan Pharma: Which Stock Should You Track

Beta Drugs vs Kopran vs Sudarshan Pharma Industries starts with the core numbers most investors compare within the pharma and biotech segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the pharma and biotech bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.

Click Here – Get Free Investment Predictions

Beta Drugs, Kopran and Sudarshan Pharma Industries: Company Overview

Beta Drugs is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,104 crore, a return on equity of 16.95% and a book value of Rs 221.65 per share. Its quarterly revenue moved from Rs 103.20 crore in June 2025 to Rs 127.13 crore in June 2026, a change of +23.2%.

Kopran is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,227 crore, a return on equity of 4.85% and a book value of Rs 109.74 per share. Its quarterly revenue moved from Rs 137.78 crore in June 2025 to Rs 156.04 crore in June 2026, a change of +13.3%.

Sudarshan Pharma Industries is a listed Indian company in the pharma and biotech space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 878 crore, a return on equity of 15.03% and a book value of Rs 6.67 per share. Its quarterly revenue moved from Rs 146.47 crore in June 2025 to Rs 175.64 crore in June 2026, a change of +19.9%.

Beta Drugs vs Kopran vs Sudarshan Pharma Industries: Valuation and Profitability Snapshot

Metric	Beta Drugs	Kopran	Sudarshan Pharma Industries
Market Cap (approx.)	Rs 2,104 crore	Rs 1,227 crore	Rs 878 crore
PE Ratio (TTM)	45.47	49.10	35.15
PB Ratio	8.56	2.31	5.27
Return on Equity (ROE)	16.95%	4.85%	15.03%
EPS (TTM, Rs)	41.74	5.17	1.00
Dividend Yield	0.00%	1.18%	0.00%
Debt to Equity	0.60	0.29	1.84
Book Value per Share (Rs)	221.65	109.74	6.67

Check the Univest Screener for Live Data

On valuation, Beta Drugs trades at a PE of 45.47 and a PB of 8.56, Kopran at a PE of 49.10 and a PB of 2.31, while Sudarshan Pharma Industries trades at a PE of 35.15 and a PB of 5.27. On return on equity, the three post 16.95%, 4.85% and 15.03% respectively, and on dividend yield they stand at 0.00%, 1.18% and 0.00%. Beta Drugs has the highest market capitalisation of the three at Rs 2,104 crore, while Sudarshan Pharma Industries has the lowest at Rs 878 crore. Kopran has the highest PE ratio of the three at 49.10, while Sudarshan Pharma Industries has the lowest at 35.15. Beta Drugs has the highest return on equity of the three at 16.95%, while Kopran has the lowest at 4.85%. Sudarshan Pharma Industries has the highest debt to equity ratio of the three at 1.84, while Kopran has the lowest at 0.29. Debt to equity is 0.60, 0.29 and 1.84 for the three respectively.

Beta Drugs vs Kopran vs Sudarshan Pharma Industries: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)	YoY Change (Net Profit)
Beta Drugs	Rs 127.13 crore	Rs 16.49 crore	+23.2%	+31.3%	+40.9%
Kopran	Rs 156.04 crore	Rs 6.70 crore	+13.3%	-33.3%	-10.1%
Sudarshan Pharma Industries	Rs 175.64 crore	Rs 5.61 crore	+19.9%	-22.0%	+41.7%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.

Beta Drugs vs Kopran vs Sudarshan Pharma Industries: Five-Quarter Revenue and Net Profit Trend

The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Beta Drugs vs Kopran vs Sudarshan Pharma Industries, which helps separate a one-quarter move from a steadier pattern.

Quarterly revenue (Rs crore)

Quarter	Beta Drugs	Kopran	Sudarshan Pharma Industries
June 2025	Rs 103.20 crore	Rs 137.78 crore	Rs 146.47 crore
September 2025	Rs 106.38 crore	Rs 117.94 crore	Rs 170.73 crore
December 2025	Rs 89.58 crore	Rs 194.35 crore	Rs 169.53 crore
March 2026	Rs 96.85 crore	Rs 234.11 crore	Rs 225.05 crore
June 2026	Rs 127.13 crore	Rs 156.04 crore	Rs 175.64 crore

Quarterly net profit (Rs crore)

Quarter	Beta Drugs	Kopran	Sudarshan Pharma Industries
June 2025	Rs 11.70 crore	Rs 7.45 crore	Rs 3.96 crore
September 2025	Rs 12.22 crore	-Rs 9.92 crore	Rs 3.87 crore
December 2025	Rs 8.52 crore	Rs 9.34 crore	Rs 4.15 crore
March 2026	Rs 9.05 crore	Rs 18.87 crore	Rs 11.39 crore
June 2026	Rs 16.49 crore	Rs 6.70 crore	Rs 5.61 crore

Beta Drugs reported revenue of Rs 103.20 crore in June 2025 and Rs 127.13 crore in June 2026, a change of +23.2% across the period. Its highest quarterly revenue in this window was Rs 127.13 crore in June 2026. Net profit stood at Rs 16.49 crore in June 2026, which is a net profit margin of 12.97%.

Kopran reported revenue of Rs 137.78 crore in June 2025 and Rs 156.04 crore in June 2026, a change of +13.3% across the period. Its highest quarterly revenue in this window was Rs 234.11 crore in March 2026. Net profit stood at Rs 6.70 crore in June 2026, which is a net profit margin of 4.29%. Kopran reported a net loss in September 2025.

Sudarshan Pharma Industries reported revenue of Rs 146.47 crore in June 2025 and Rs 175.64 crore in June 2026, a change of +19.9% across the period. Its highest quarterly revenue in this window was Rs 225.05 crore in March 2026. Net profit stood at Rs 5.61 crore in June 2026, which is a net profit margin of 3.19%.

Download the Univest iOS App or Univest Android App to track Beta Drugs, Kopran and Sudarshan Pharma Industries live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma and biotech names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as contract manufacturing orders, plant utilisation, regulatory inspections and input cost trends. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.

It also helps to read the latest quarterly filings and investor presentations of Beta Drugs, Kopran and Sudarshan Pharma Industries directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.

Conclusion

Beta Drugs vs Kopran vs Sudarshan Pharma Industries highlights how differently three companies in the same pharma and biotech segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Beta Drugs vs Kopran vs Sudarshan Pharma Industries

What is the market cap difference between Beta Drugs, Kopran and Sudarshan Pharma Industries?

Ans. As of October 2026, Beta Drugs has a market cap of approximately Rs 2,104 crore, Kopran is at approximately Rs 1,227 crore, and Sudarshan Pharma Industries is at approximately Rs 878 crore. Beta Drugs is the largest of the three, and its market capitalisation is about 2.4 times that of Sudarshan Pharma Industries, the smallest. Market capitalisation reflects the size of a company in the market rather than the quality of its business, so a larger value does not by itself signal a higher quality company. These figures move with the share price every trading day, which is why the table above should be read as a snapshot rather than a fixed ranking in the Beta Drugs vs Kopran vs Sudarshan Pharma Industries comparison.

What are the PE and PB ratios of Beta Drugs, Kopran and Sudarshan Pharma Industries?

Ans. As of October 2026, the PE ratios stand at 45.47, 49.10 and 35.15 respectively, and the price to book ratios stand at 8.56, 2.31 and 5.27 respectively. All three companies have a positive trailing PE, so the multiples can be compared directly. The PE ratio shows how much investors pay for each rupee of trailing earnings, while the PB ratio compares the market value with the net assets on the balance sheet. Both multiples should be read against the segment norms for pharma and biotech and against each company's own growth and earnings stability, because a high multiple can reflect expected growth or simply a small earnings base.

Which of the three has the highest ROE?

Ans. Beta Drugs, Kopran and Sudarshan Pharma Industries post ROE of 16.95%, 4.85% and 15.03% respectively as of October 2026. Beta Drugs has the highest return on equity of the three at 16.95%, while Kopran has the lowest at 4.85%. Return on equity measures how much profit a company generates on the capital contributed by its shareholders, so it is a useful gauge of how efficiently equity is being used. A negative ROE points to losses over the period, and a very high ROE can sometimes result from a small equity base rather than operating performance. It is therefore worth reading ROE together with debt levels and the five-quarter profit trend before drawing any conclusion from the Beta Drugs vs Kopran vs Sudarshan Pharma Industries figures.

Which of these three stocks pays the highest dividend yield?

Ans. Beta Drugs, Kopran and Sudarshan Pharma Industries carry dividend yields of 0.00%, 1.18% and 0.00% respectively as of October 2026. Dividend yield is the annual dividend per share expressed as a percentage of the current share price, so it changes whenever the price changes. A low or zero yield is common among companies that retain profits to fund expansion, repay debt or absorb losses, and it does not by itself say anything about business quality. Investors who care about income should also check how consistently each company has paid dividends and what share of profit it distributes.

What is the debt to equity ratio for Beta Drugs, Kopran and Sudarshan Pharma Industries?

Ans. Beta Drugs carries a debt to equity of 0.60, Kopran of 0.29, and Sudarshan Pharma Industries of 1.84. Sudarshan Pharma Industries has the highest debt to equity ratio of the three at 1.84, while Kopran has the lowest at 0.29. The debt to equity ratio compares total borrowings with shareholders' funds, and a higher figure means the company relies more on borrowed money to run its business. What counts as a comfortable level differs by segment, since some businesses in pharma and biotech need heavy capital and carry more debt than others. Investors usually read this ratio alongside interest costs and cash generation to judge how well each company can service its borrowings in the Beta Drugs vs Kopran vs Sudarshan Pharma Industries comparison.

What were the latest quarterly revenue and net profit of Beta Drugs, Kopran and Sudarshan Pharma Industries?

Ans. For Q1 FY27 (quarter ended June 2026), Beta Drugs reported revenue of Rs 127.13 crore and net profit of Rs 16.49 crore, Kopran reported revenue of Rs 156.04 crore and net profit of Rs 6.70 crore, and Sudarshan Pharma Industries reported revenue of Rs 175.64 crore and net profit of Rs 5.61 crore. Compared with the quarter ended June 2025, revenue changed by +23.2% for Beta Drugs, +13.3% for Kopran and +19.9% for Sudarshan Pharma Industries. A single quarter can be affected by seasonality, one-time items and the timing of orders, so the five-quarter tables above give a clearer sense of direction than any one result. A net loss in a quarter does not always mean a troubled business, but it does call for a closer look at costs, debt and the reasons behind the swing in the Beta Drugs vs Kopran vs Sudarshan Pharma Industries results.

Does this comparison recommend one of Beta Drugs, Kopran and Sudarshan Pharma Industries?

Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research. Instead of a verdict, the tables above lay out the figures so that readers can weigh them against their own goals, time horizon and tolerance for risk. For companies in pharma and biotech, it also helps to look at factors such as contract manufacturing orders, plant utilisation, regulatory inspections and input cost trends. Reading the latest filings and investor presentations of Beta Drugs, Kopran and Sudarshan Pharma Industries directly, and speaking to a SEBI registered adviser where needed, is a sensible step before acting on any numbers shown in Beta Drugs vs Kopran vs Sudarshan Pharma Industries.